Executive DirectorVice President, Commercial Operations (Tumor HI Program)
Job Location:
Redwood City, CA - USA
Monthly Salary:
Posted:
Application Deadline:
Vacancies:
Job Summary
Rezolute is a late-stage rare disease biopharmaceutical company focused on developing transformative therapies for patients living with severe metabolic and endocrine disorders. Our mission is to bring hope and meaningful solutions to patients and families affected by rare and difficult-to-treat diseases through scientific innovation collaboration and integrity.
Rezolutes lead investigational therapy RZ358 (ersodetug) is a fully human monoclonal antibody in late-stage clinical development for the treatment of hypoglycemia due to congenital and acquired forms of hyperinsulinism (HI). As Rezolute expands its medical and scientific focus into tumor-related hyperinsulinism (tumor HI) most commonly related to pancreatic neuroendocrine tumors (insulinomas) or paraneoplastic hypoglycemia (NICTH) the company is committed to advancing novel therapeutic strategies that address this rare and complex form of hypoglycemia associated with insulin-secreting tumors and related neuro-oncology disorders.
Position Summary
We are seeking a dynamic and experienced Executive Director/Vice President of Commercial Operations to establish and lead all operational aspects of our commercial strategy in support of the launch of our first rare disease therapy. This includes managing commercial operations functions ensuring the infrastructure processes and strategies necessary for successful product launch. This individual will be a strategic and hands-on leader responsible for building and managing critical commercial infrastructure including sales operations analytics forecasting market access operations and commercial systems. This role oversees sales operations forecasting and analytics incentive compensation market research data management CRM systems field effectiveness and commercial training.
The ideal candidate has experience in rare disease or specialty pharmaceutical markets and thrives in an entrepreneurial fast-paced environment. The ideal candidate has experience in rare disease or specialty pharmaceutical markets and thrives in an entrepreneurial fast-paced environment.
This role is based in the home office and requires minimum of 3 days per week in the office.
- Serve as a key member of the Commercial Leadership Team developing and executing commercial strategy and operations plans.
- Develop and execute the commercial operations infrastructure to support a successful rare disease product launch.
- Lead commercial planning processes including sales forecasting demand planning incentive compensation design and territory alignment.
- Build and oversee a high-functioning sales operations team and associated systems (CRM data warehousing reporting dashboards).
- Establish data governance processes and manage third-party vendors providing data (claims specialty pharmacy distribution).
- Partner cross-functionally with Market Access Marketing Medical Affairs Finance and IT to ensure alignment of commercial operations with overall corporate goals.
- Design and manage KPIs and reporting frameworks to track performance and inform commercial decision-making.
- Lead field force enablement efforts including CRM configuration targeting call planning and field reporting.
- Support the development of compliant policies and processes for commercial activities in collaboration with Legal and Compliance teams.
- Manage operational budgets contracts and vendor relationships for commercial functions.
- Bachelors degree required; MBA or advanced degree preferred.
- 10 years of progressive experience in commercial operations within the biopharmaceutical industry including at least 5 years in a leadership role.
- Direct experience supporting launch planning and execution for rare disease or specialty products.
- Deep understanding of commercial data sources (e.g. specialty pharmacy HUB services patient services claims data).
- Demonstrated success in building commercial infrastructure in a high-growth or startup environment.
- Strong project management skills attention to detail and ability to lead cross-functional initiatives.
- Excellent communication and leadership skills with a collaborative approach.
- Familiarity with compliance regulations in the rare disease space.
Preferred Attributes
- Experience in both pre-commercial and commercial-stage biotech organizations.
- Entrepreneurial mindset and comfort operating in a fast-paced evolving environment.
- Ability to work in a lean organization with a hands-on roll-up-your-sleeves style.
- Passion for serving patients with serious or underserved diseases.
Rezolute (RZLT) currently anticipates the base salary for the Executive Director/Vice President of Commercial Operations role could range from $290000 to $340000 and will depend in part on the successful candidates geographical location and their qualifications for the role including education and experience. This position will also be eligible for an annual performance bonus in accordance with the terms of the applicable plan (depending in part on company and individual performance and at the Companys discretion on an individual basis). The compensation described above is subject to change and could be higher or lower than the range described based on current market survey data and the qualifications education experience and geographical location of the selected candidate.
Qualifying employees are eligible to participate in benefit programs such as:
- Health Insurance (Medical / Dental / Vision)
- Disability Life & Long-Term Care Insurance
- Holiday Pay
- Tracking Free Vacation Program
- 401(k) Plan Match
- Educational Assistance Benefit
- Fitness Center Reimbursement
We are an Equal Opportunity Employer and do not discriminate against applicants due to race ethnicity gender veteran status or on the basis of disability or any other federal state or local protected class.
Required Experience:
Exec
About Company
Rezolute is a clinical‑stage biopharmaceutical company developing transformative therapies—such as the monoclonal antibody ersodetug (RZ358) in Phase 3 for congenital hyperinsulinism and the oral plasma kallikrein inhibitor RZ402 in Phase 2 for diabetic macular edema—to treat rare met ... View more
